Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jessica Dickens"'
Publikováno v:
Cancer Research. 81:471-471
Immune Checkpoint Inhibitor (ICI) therapies continue to revolutionize treatment of advanced malignancies. However, identification of individuals who respond to ICI treatment remains challenging. Along with programmed death ligand 1(PD-L1 aka CD274) e
Autor:
Jessica Dickens, Rajeswari Vemula, Matthew G. Butler, Catherine Huang, Bharathi Anekella, Omoshile Clement, Yves Konigshofer
Publikováno v:
Cancer Research. 81:2232-2232
Purpose: Whole transcriptome RNA-sequencing (RNA-Seq) has emerged as one of the most effective methods for detection of genomic rearrangements in cancer. Enrichment for poly(A) + RNA as part of library preparation is a standard method to select for m
Autor:
Praveena Kamineni, Ram Santhanam, Jessica Dickens, Bharathi Anekella, Omoshile Clement, Dan Brudzewsky, Catherine Huang, Farol L. Tomson
Publikováno v:
Cancer Research. 80:4315-4315
The large range of genetic aberrations and genes involved Myeloid malignancies, clonal diseases of hematopoietic progenitor cells which can lead to accumulation of immature blast cells in the bone marrow and peripheral blood, make Next Generation Seq
Autor:
Bharathi Anekella, Russell Garlick, Omoshile Clement, Dan Brudzewsky, Jessica Dickens, Yves Konigshofer, Andrew Anfora, Matthew G. Butler
Publikováno v:
Cancer Research. 80:1978-1978
Here we describe reference materials for measurable residual disease (MRD) assay design and validation as well as initial data from testing. The analytical validation of liquid biopsy-based assays that attempt to monitor for the disappearance and ree
Autor:
Bharathi Anekella, Matthew G. Butler, Jessica Dickens, Russell Garlick, Yves Konigshofer, Karl G. Sylvester, Katherine Bianco
Publikováno v:
Cancer Research. 78:5569-5569
The limited quantities of ccfDNA in plasma can make it difficult to assess the sensitivities and specificities of circulating tumor DNA (ctDNA) assays because there is often insufficient material to confirm the presence or absence of particular mutat
Publikováno v:
Cancer Research. 78:4540-4540
Introduction: Copy number variation (CNV), including gene amplification and deletion, can be a key driver of oncogenesis. Pathogenic CNVs are often associated with unfavorable prognosis and drug resistance, therefore detection of these types of genet
Publikováno v:
Cancer Research. 77:738-738
Introduction: Genomic instability is a hallmark of cancer, and copy number variation (CNV), including gene duplication and deletion, can be a key driver of oncogenesis. Detection of CNV is needed for personalized treatment, and may involve microarray